These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31486951)

  • 1. Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity.
    Nelson LM; DiBenedetti D; Pariser DM; Glaser DA; Hebert AA; Hofland H; Drew J; Ingolia D; Gillard KK; Fehnel S
    J Patient Rep Outcomes; 2019 Sep; 3(1):59. PubMed ID: 31486951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.
    Kirsch BM; Burke L; Hobart J; Angulo D; Walker PS
    J Drugs Dermatol; 2018 Jul; 17(7):707-714. PubMed ID: 30005091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing asthma symptoms in children: qualitative research supporting the development of the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O).
    Bradley H; Trennery C; Jones AM; Lydon A; White F; Williams-Hall R; Arbuckle R; Tomaszewski E; Shih VH; Haughney J; Eisen A; Winders T; Coons SJ; Eremenco S;
    J Patient Rep Outcomes; 2023 Oct; 7(1):104. PubMed ID: 37863864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD).
    Molin S; Larsen LS; Joensson P; Oesterdal ML; Arbuckle R; Grant L; Skingley G; Schuttelaar MLA
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):643-669. PubMed ID: 38485862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
    Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric validation and testing of the 10-item pediatric daily chest-related electronic patient reported outcome (ePRO) diary.
    Arbuckle R; Shea T; Burrows K; Marshall C; Trigg A; Stein J; Albrecht HH
    J Patient Rep Outcomes; 2023 Jan; 7(1):6. PubMed ID: 36695911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Item-level psychometric properties for a new patient-reported psoriasis symptom diary.
    Strober BE; Nyirady J; Mallya UG; Guettner A; Papavassilis C; Gottlieb AB; Elewski BE; Turner-Bowker DM; Shields AL; Gwaltney CJ; Lebwohl M
    Value Health; 2013; 16(6):1014-22. PubMed ID: 24041351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.
    Chan EKH; Williams V; Romano C; Fehnel S; Slagle AF; Stoddard J; Sadoff J; Mayorga M; Lewis S; Yarr S; Ma J; Liu Y; Katz EG; McNulty P; van Dromme I; McQuarrie K
    J Patient Rep Outcomes; 2023 May; 7(1):45. PubMed ID: 37195456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain.
    Wyrwich KW; O'Brien CF; Soliman AM; Chwalisz K
    Reprod Sci; 2018 Nov; 25(11):1567-1576. PubMed ID: 30033855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development and validation of a disease-specific quality of life measure in hyperhidrosis: the Hyperhidrosis Quality of Life Index (HidroQOL©).
    Kamudoni P; Mueller B; Salek MS
    Qual Life Res; 2015 Apr; 24(4):1017-27. PubMed ID: 25367139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the Presbyopia Impact and Coping Questionnaire.
    Johnson N; Shirneshan E; Coon CD; Stokes J; Wells T; Lundy JJ; Andrae DA; Evans CJ; Campbell J
    Ophthalmol Ther; 2021 Dec; 10(4):1057-1075. PubMed ID: 34643894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures.
    Gater A; Nelsen L; Coon CD; Eremenco S; O'Quinn S; Khan AH; Eckert L; Staunton H; Bonner N; Hall R; Krishnan JA; Stoloff S; Schatz M; Haughney J; Coons SJ;
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1249-1259. PubMed ID: 34896298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.
    Kawata AK; Hsieh R; Bender R; Shaffer S; Revicki DA; Bayliss M; Buse DC; Desai P; Sapra S; Ortmeier B; Hareendran A
    Headache; 2017 Oct; 57(9):1385-1398. PubMed ID: 28857154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17). part 1: development and content validity.
    Morris S; Li Y; Smith JAM; Dube' S; Burbridge C; Symonds T
    BMC Musculoskelet Disord; 2017 May; 18(1):195. PubMed ID: 28511678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an electronic daily uterine fibroid symptom diary.
    Deal LS; Williams VS; Fehnel SE
    Patient; 2011; 4(1):31-44. PubMed ID: 21766892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.
    Mathias SD; Vallow S; Gipson DS; Thorneloe KS; Sprecher D
    Am J Kidney Dis; 2017 Oct; 70(4):532-540. PubMed ID: 28663063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of the AFImpact: An Atrial Fibrillation-Specific Measure of Patient-Reported Health-Related Quality of Life.
    Coyne KS; Edvardsson N; Rydén A
    Value Health; 2017 Dec; 20(10):1355-1361. PubMed ID: 29241895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.